AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 302 min read$LLY

Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr

Eli Lilly (LLY) reported positive Phase 3 trial results for Foundayo, showing cardiovascular benefits in type 2 diabetes patients. The drug matched insulin glargine in preventing major adverse cardiovascular events while improving A1C levels and weight reduction. Foundayo reduced serious cardiovascular risks by 16%, cardiovascular mortality by 53%, and overall mortality by 57%.

Original reporting
gurufocus.com
Published Sep 30, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 11:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The data positions Lilly for a possible new blockbuster in the diabetes‑obesity market, likely influencing analyst forecasts and investor sentiment.

02

Market read

First‑report Phase 3 data for a large‑cap pharma could move the stock and affect the broader cardiometabolic sector.

03

What to watch

Potential safety concerns or delayed FDA filing could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Eli Lilly announced Phase 3 results for its experimental drug Foundayo (orforglipron) at the European Association for the Study of Diabetes meeting.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase 3 ACHIEVE-4 trial showed a 16% reduction in major adverse cardiovascular events and a 53% cut in cardiovascular mortality for Foundayo.

Expected impact

likely upward pressure as market prices in the trial success

Evidence & confidence

The trial results are a primary disclosure for a large‑cap biotech; investors typically react quickly to pivotal data.

Market effects

Sector

strengthens the cardiometabolic drug sector and may spur competitor R&D activity

Regional

U.S. equities

Global

global, given worldwide diabetes prevalence

Counterpoint

What could challenge this read

If the trial data fails to translate into regulatory approval, the rally could be short‑lived.

Key entities

  • company
    Eli Lilly and Co

    Pharmaceutical company reporting trial results

  • product
    Foundayo (orforglipron)

    Experimental GLP‑1 agonist evaluated in ACHIEVE-4 trial

Read at source← All news

Related articles

SEP 30
$LLYMedAI 8/10

Retatrutide Yields Significant Weight Loss in T2D

Eli Lilly's phase 3 TRIUMPH-2 study shows retatrutide, a triple hormonal agonist, achieved significant weight loss (up to 20.8%) and glycemic improvements in adults with type 2 diabetes (T2D) and obesity. The study, presented at EASD 2026, involved 1152 participants and showed retatrutide's efficacy estimand exceeded 20% weight reduction, a threshold not previously reached in T2D patients.

medscape.com3 min
SEP 30
$LLYMedAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study | Eli Lilly and Company

Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), showed cardiovascular safety and sustained A1C reduction in the ACHIEVE-4 trial. Participants had a 16% lower risk of MACE-4 and 23% lower risk of MACE-3 vs. insulin glargine. Foundayo also demonstrated weight loss and improved cardiovascular risk factors. The trial involved 2,749 adults with type 2 diabetes and obesity or overweight.

investor.lilly.com3 min
SEP 30
$LLYHighAI 8/10

Weight-loss-drug makers unveil new data and deals

Eli Lilly presented Phase 3 data for retatrutide, showing 23% weight loss and significant blood sugar reductions. Novo Nordisk and Genentech licensed weight-loss molecules from Jiangsu Hengrui and Hanmi Pharmaceuticals, respectively, for upfront payments of $300M and $190M. Roche abandoned its obesity drug, emugrobart, after Phase 2 trial failures.

acs.org3 min
SEP 30
$LLYHighAI 8/10

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

Eli Lilly's Foundayo (orforglipron) showed a 16% lower risk of major cardiovascular events and 23% lower risk of cardiovascular death, heart attack, or stroke compared to insulin glargine in the ACHIEVE-4 trial. The drug also demonstrated improvements in A1C, weight, and other cardiometabolic health measures. Lilly plans to present these results at the EASD meeting and publish them in The Lancet.

prnewswire.com2 min
SEP 30
$LLYMedAI 9/10

Eli Lilly Diabetes Drug Spurs Record Weight Loss in Trials

Eli Lilly's experimental weight-loss drug retatrutide showed significant results in trials, with participants losing up to 60-70 pounds. The drug also improved blood-sugar levels, with some diabetes patients achieving remission. The company plans to seek FDA approval next year, according to trial results published in the Lancet and the New England Journal of Medicine.

newser.com2 min
SEP 30
$LLYMedAI 8/10

Eli Lilly And Company Announces New Phase 3b ADtouch Data Showing EBGLYSS Delivers Significant Improvements In Skin Clearance, Itch, Pain And Patient Satisfaction In Moderate-To-Severe Hand And Foot Atopic Dermatitis

Eli Lilly announced positive Phase 3b ADtouch trial results for EBGLYSS, showing significant improvements in hand and foot skin clearance, itch, pain, and patient satisfaction in moderate-to-severe atopic dermatitis. The trial met primary and secondary endpoints at Week 16, with patient-reported outcomes and quality of life improvements.

marketscreener.com2 min